MedTrace Logo

Effect of N-acetylcysteine on Brain Glutamate

NCT02483130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2018-03-08

No results posted yet for this study

Summary

A double-blind, placebo controlled, crossover study to determine whether a single dose of N-acetylcysteine (a nutritional supplement) can reduce brain glutamate levels in patients with a psychotic disorder. Secondary outcomes are to determine the pattern of alteration in brain perfusion and activity following a single dose of N-acetylcysteine.

Conditions

Interventions

DIETARY_SUPPLEMENT

N-Acetylcysteine

Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.

OTHER

Placebo

Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.

Sponsors & Collaborators

Principal Investigators

  • James H McCabe · King's College London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • United Kingdom

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02483130 on ClinicalTrials.gov